BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 32406915)

  • 1. The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation.
    Maslow BL; Guarnaccia M; Stefanacci C; Ramirez L; Klein JU
    Hum Reprod; 2020 May; 35(5):1054-1060. PubMed ID: 32406915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
    Zhou C; Yang X; Wang Y; Xi J; Pan H; Wang M; Zhou Y; Xiao Y
    Hum Reprod; 2022 Jul; 37(8):1795-1805. PubMed ID: 35595223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
    Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
    Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study.
    Haas J; Bassil R; Samara N; Zilberberg E; Mehta C; Orvieto R; Casper RF
    Hum Reprod; 2020 Jul; 35(7):1648-1654. PubMed ID: 32563188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
    Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
    Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.
    Lobo R; Soerdal T; Ekerhovd E; Cohlen B; Porcu E; Schenk M; Shufaro Y; Smeenk J; Suerdieck MB; Pinton P; Pinborg A;
    Hum Reprod; 2024 May; ():. PubMed ID: 38723189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does dual oocyte retrieval with continuous FSH administration increase the number of mature oocytes in low responders? An open-label randomized controlled trial.
    Boudry L; Mateizel I; Wouters K; Papaleo E; Mackens S; De Vos M; Racca A; Adriaenssens T; Tournaye H; Blockeel C
    Hum Reprod; 2024 Mar; 39(3):538-547. PubMed ID: 38199789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
    Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
    Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
    Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM; Humaidan P; Alviggi C
    Hum Reprod; 2021 Jul; 36(8):2157-2169. PubMed ID: 34179973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
    Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
    Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
    Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
    Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
    Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials.
    Humaidan P; Nelson SM; Devroey P; Coddington CC; Schwartz LB; Gordon K; Frattarelli JL; Tarlatzis BC; Fatemi HM; Lutjen P; Stegmann BJ
    Hum Reprod; 2016 Sep; 31(9):1997-2004. PubMed ID: 27343272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
    Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
    Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No effect of ovarian stimulation and oocyte yield on euploidy and live birth rates: an analysis of 12 298 trophectoderm biopsies.
    Irani M; Canon C; Robles A; Maddy B; Gunnala V; Qin X; Zhang C; Xu K; Rosenwaks Z
    Hum Reprod; 2020 May; 35(5):1082-1089. PubMed ID: 32348476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.